{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:25:59Z","timestamp":1792571159250,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore whether elevated anti-M\u00fcllerian hormone (AMH) levels affect the rate of preterm birth (PTB) among PCOS patients with different BMIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective cohort study, patients with PCOS who had undergone IVF\/ICSI from January 2017 to December 2019 were included for potential evaluation. A total of 2368 singleton live births from PCOS patients were included. According to the BMI, all the PCOS patients were divided into two groups: BMI&amp;lt;24 kg\/m<jats:sup>2<\/jats:sup> and BMI\u226524 kg\/m<jats:sup>2<\/jats:sup>. In total, 1339 PCOS patients with a BMI&amp;lt;24 kg\/m<jats:sup>2<\/jats:sup> were grouped according to their serum AMH levels: \u2460 &amp;lt;2.71 ng\/ml (n=333), \u2461 2.71-4.08 ng\/ml (n=330), \u2462 4.09-6.45 ng\/ml (n=351), and \u2463 &amp;gt;6.45 ng\/ml (n=325). Additionally, 1029 cycles of patients with a BMI\u226524 kg\/m<jats:sup>2<\/jats:sup> were grouped according to the serum AMH level: \u2460 &amp;lt;2.71 ng\/ml (n=255), \u2461 2.71-4.08 ng\/ml (n=267), \u2462 4.09-6.45 ng\/ml (n=239), and \u2463 &amp;gt;6.45 ng\/ml (n=268), with &amp;lt;2.71 ng\/ml being considered the reference group. The grouping was based mainly on the interquartile range of serum AMH levels. The primary outcome of the study was PTB. The secondary outcomes were low birth weight (LBW), small for gestational age (SGA), macrosomia and large for gestational age (LGA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Regarding PCOS patients with a BMI&amp;lt;24 kg\/m<jats:sup>2<\/jats:sup>, compared with the PTB rate of the AMH &amp;lt;2.71 ng\/ml group, the PTB rates of the different groups were not significantly different (AMH 2.71-4.08, AOR (95% CI)=1.01 (0.52-2.00), P=0.99; AMH 4.09-6.45, AOR (95% CI)=0.93 (0.45-1.91), P=0.85; AMH&amp;gt;6.45, AOR (95% CI)=0.78 (0.35-1.73), P=0.54). Regarding PCOS patients with a BMI \u226524 kg\/m<jats:sup>2<\/jats:sup>, compared with the PTB rate of the AMH &amp;lt;2.71 ng\/ml group, the PTB rate of the AMH&amp;gt;6.45 ng\/ml group was significantly higher (OR=2.47; 95% CI=1.34-4.55). After multiple logistic regression analysis, the risk of PTB in the AMH&amp;gt;6.45 ng\/ml group was 2.1 times that in the AMH&amp;lt;2.71 ng\/ml group (AOR=2.1, 95% CI=1.01-4.37, P=0.04). However, no statistically significant difference was found in the rate of SGA, LBW, macrosomia or LGA among patients in the different serum AMH groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>For PCOS patients, a BMI\u226524 kg\/m<jats:sup>2<\/jats:sup> plus serum AMH&amp;gt;6.45 ng\/ml (75th percentile) is an independent risk factor for PTB.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.788000","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T04:42:00Z","timestamp":1638938520000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Elevated Anti-M\u00fcllerian Hormone Is an Independent Risk Factor for Preterm Birth Among Patients With Overweight Polycystic Ovary Syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Mingze","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","article-title":"Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome","volume":"81","year":"2004","journal-title":"Fertil Steril"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0178","article-title":"Positions Statement: Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew218","article-title":"The Prevalence and Phenotypic Features of Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dep399","article-title":"The Prevalence of Polycystic Ovary Syndrome in a Community Sample Assessed Under Contrasting Diagnostic Criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/det262","article-title":"Prevalence of Polycystic Ovary Syndrome in Women in China: A Large Community-Based Study","volume":"28","author":"Li","year":"2013","journal-title":"Hum Reprod"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/clep.s37559","article-title":"Epidemiology, Diagnosis, and Management of Polycystic Ovary Syndrome","volume":"6","author":"Sirmans","year":"2013","journal-title":"Clin Epidemiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2019.03.203","article-title":"A Meta-Analysis of Pregnancy-Related Outcomes and Complications in Women With Polycystic Ovary Syndrome Undergoing IVF","volume":"39","author":"Sha","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.06.015","article-title":"Highly Elevated Level of Antim\u00fcllerian Hormone Associated With Preterm Delivery in Polycystic Ovary Syndrome Patients Who Underwent Ovulation Induction","volume":"115","author":"Kaing","year":"2021","journal-title":"Fertil Steril"},{"key":"B9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.fertnstert.2019.09.039","article-title":"High Antim\u00fcllerian Hormone Levels Are Associated With Preterm Delivery in Patients With Polycystic Ovary Syndrome","volume":"113","author":"Hu","year":"2020","journal-title":"Fertil Steril"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01320","article-title":"M\u00fcllerian-Inhibiting Substance\/Anti-M\u00fcllerian Hormone as a Predictor of Preterm Birth in Polycystic Ovary Syndrome","volume":"103","author":"Hsu","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(86)90783-x","article-title":"Isolation of the Bovine and Human Genes for M\u00fcllerian Inhibiting Substance and Expression of the Human Gene in Animal Cells","volume":"45","author":"Cate","year":"1986","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmp036","article-title":"Anti-Mullerian Hormone (AMH) as a Predictive Marker in Assisted Reproductive Technology (ART)","volume":"16","author":"La Marca","year":"2010","journal-title":"Hum Reprod Update"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030727","article-title":"Elevated Serum Level of Anti-Mullerian Hormone in Patients With Polycystic Ovary Syndrome: Relationship to the Ovarian Follicle Excess and to the Follicular Arrest","volume":"88","author":"Pigny","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2076","article-title":"Serum Anti-Mullerian Hormone as a Surrogate for Antral Follicle Count for Definition of the Polycystic Ovary Syndrome","volume":"91","author":"Pigny","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030932","article-title":"Anti-M\u00fcllerian Hormone Serum Concentrations in Normoovulatory and Anovulatory Women of Reproductive Age","volume":"89","author":"Laven","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2425","article-title":"Serum Anti-Mullerian Hormone Concentrations Are Not Altered by Acute Administration of Follicle Stimulating Hormone in Polycystic Ovary Syndrome and Normal Women","volume":"92","author":"Wachs","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.07.046","article-title":"M\u00fcllerian Inhibiting Substance and Disrupted Folliculogenesis in Polycystic Ovary Syndrome","volume":"196","author":"Wang","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh373","article-title":"Changes in Anti-M\u00fcllerian Hormone Serum Concentrations Over Time Suggest Delayed Ovarian Ageing in Normogonadotrophic Anovulatory Infertility","volume":"19","author":"Mulders","year":"2004","journal-title":"Hum Reprod"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2019.1613640","article-title":"Correlation of Body Mass Index (BMI), Anti-Mullerian Hormone (AMH), and Insulin Resistance Among Different Polycystic Ovary Syndrome (PCOS) Phenotypes - A Cross-Sectional Study","volume":"35","author":"Gupta","year":"2019","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deq028","article-title":"Appropriate BMI Levels for PCOS Patients in Southern China","volume":"25","author":"Chen","year":"2010","journal-title":"Hum Reprod"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01912-1","article-title":"Body Fat Indices as Effective Predictors of Insulin Resistance in Obese\/Non-Obese Polycystic Ovary Syndrome Women in the Southwest of China","volume":"65","author":"Huang","year":"2019","journal-title":"Endocrine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S2040174421000234","article-title":"Supraphysiological Estradiol Levels on the hCG Trigger Day Are Associated With SGA for Singletons Born From Fresh Embryo Transfer","volume":"11","author":"Zhang","year":"2021","journal-title":"J Dev Orig Health Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13048-018-0432-x","article-title":"Fresh Versus Frozen Embryo Transfer for Full-Term Singleton Birth: A Retrospective Cohort Study","volume":"11","author":"Zhang","year":"2018","journal-title":"J Ovarian Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104779","article-title":"Birth Weight Reference Percentiles for Chinese","volume":"9","author":"Dai","year":"2014","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmv029","article-title":"Pregnancy Complications in Women With Polycystic Ovary Syndrome","volume":"21","author":"Palomba","year":"2015","journal-title":"Hum Reprod Update"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex239","article-title":"Use of the Serum Anti-M\u00fcllerian Hormone Assay as a Surrogate for Polycystic Ovarian Morphology: Impact on Diagnosis and Phenotypic Classification of Polycystic Ovary Syndrome","volume":"32","author":"Fraissinet","year":"2017","journal-title":"Hum Reprod"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2009.11.002","article-title":"Serum Antimullerian Hormone (AMH) Levels Are Elevated in Adolescent Girls With Polycystic Ovaries and the Polycystic Ovarian Syndrome (PCOS)","volume":"94","author":"Hart","year":"2010","journal-title":"Fertil Steril"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0035-5","article-title":"Elevated Prenatal Anti-M\u00fcllerian Hormone Reprograms the Fetus and Induces Polycystic Ovary Syndrome in Adulthood","volume":"24","author":"Tata","year":"2018","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3109\/14767050903042561","article-title":"Maternal BMI and Preterm Birth: A Systematic Review of the Literature With Meta-Analysis","volume":"22","author":"Torloni","year":"2009","journal-title":"J Maternal-Fetal Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-010-1740-6","article-title":"Maternal Early Pregnancy Body Mass Index and Risk of Preterm Birth","volume":"284","author":"Wang","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12884-019-2611-1","article-title":"Effects of Pre-Pregnancy Body Mass Index on Pregnancy and Perinatal Outcomes in Women with PCOS Undergoing Frozen Embryo Transfer","volume":"19","author":"Lin","year":"2019","journal-title":"BMC Pregnancy Childbirth"},{"key":"B32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/biolre\/iox151","article-title":"Mice With Either Diminished or Elevated Levels of Anti-M\u00fcllerian Hormone Have Decreased Litter Sizes","volume":"98","author":"McLennan","year":"2018","journal-title":"Biol Reprod"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.01.028","article-title":"Evidence for a M\u00fcllerian-Inhibiting Substance Autocrine\/Paracrine System in Adult Human Endometrium","volume":"91","author":"Wang","year":"2009","journal-title":"Fertil Steril"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9565","article-title":"M\u00fcllerian Inhibiting Substance\/Anti-M\u00fcllerian Hormone Type II Receptor Protein and mRNA Expression in the Healthy and Cancerous Endometria","volume":"17","author":"Kim","year":"2019","journal-title":"Oncol Lett"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/mrd.20858","article-title":"A Mesenchymal Perspective of M\u00fcllerian Duct Differentiation and Regression in Amhr2-lacZ Mice","volume":"75","author":"Arango","year":"2008","journal-title":"Mol Reprod Dev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.5468\/ogs.2018.61.1.127","article-title":"The Expression of M\u00fcllerian Inhibiting Substance\/Anti-M\u00fcllerian Hormone Type II Receptor in Myoma and Adenomyosis","volume":"61","author":"Kim","year":"2018","journal-title":"Obstet Gynecol Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ejogrb.2009.02.044","article-title":"Integration of Endocrine and Mechanical Signals in the Regulation of Myometrial Functions During Pregnancy and Labour","volume":"144","author":"Shynlova","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.788000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T04:42:02Z","timestamp":1638938522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.788000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":37,"alternative-id":["10.3389\/fendo.2021.788000"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.788000","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]},"article-number":"788000"}}